(Q36438845)

14 August 2017

1 reference

1 February 2021

The safety profile of drotrecogin alfa (activated). (English)

1 reference

randomized controlled trial

14 August 2017

1 reference

multiple organ dysfunction syndrome

19 September 2019

1 reference

1 October 2020

1 reference

1 February 2021

Protein C, inactivator of coagulation factors Va and VIIIa

1 reference

1 February 2021

1 reference

1 reference

PubMed publication ID

18269693

bleeding

1 reference

PubMed publication ID

18269693

author name string

Roberto Fumagalli

series ordinal

1

1 reference

14 August 2017

Mariano A Mignini

series ordinal

2

1 reference

14 August 2017

1 January 2007

1 reference

14 August 2017

9 references

14 August 2017

22 June 2019

4 August 2019

19 September 2019

18 November 2019

27 November 2019

21 December 2019

1 October 2020

1 February 2021

11 Suppl 5

1 reference

14 August 2017

S6

1 reference

https://scigraph.springernature.com/pub.10.1186/cc6157

14 August 2017

0 references

cites work

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Evaluating the use of Drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

The cytoprotective protein C pathway

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Drotrecogin alfa (activated) in the treatment of severe sepsis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Efficacy and safety of drotrecogin alfa (activated) for the therapy of surgical patients with severe sepsis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Coagulation abnormalities in critically ill patients

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

New insights into the protein C pathway: potential implications for the biological activities of drotrecogin alfa (activated).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Efficacy and safety of recombinant human activated protein C for severe sepsis

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Spontaneous intracerebral hemorrhage in critically ill patients: incidence over six years and associated factors

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Second course of recombinant human activated protein C delivered to a severely septic patient after recent surgery

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

The neuropathology of septic shock.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2230610

Human protein C: inactivation of factors V and VIII in plasma by the activated molecule

21 September 2018

1 reference

12 December 2020

Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

1 reference

12 December 2020

Results of severe sepsis treatment program using recombinant human activated protein C in Poland

1 reference

12 December 2020

ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation

1 reference

12 December 2020

Safety of drotrecogin alfa (activated): a fair comparison requires consistent definitions

1 reference

12 December 2020

Is there increasing evidence that the risks of rhAPC may outweigh its benefits?

1 reference

12 December 2020

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)

1 reference

12 December 2020

Identifiers

DOI

10.1186/CC6157

1 reference

Dimensions Publication ID

14 August 2017

0 references

1 reference

14 August 2017

PubMed publication ID

18269693

1 reference